Brivaracetam

Generic name
Brivaracetam
Brand name
ATC Code
N03AX23
Compare …

Brivaracetam

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Population pharmacokinetics modeling was performed based on sparse plasma concentration data (n=232, leeftijd 2 mnd-17 jaar). The analysis indicated that doses of 5.0 (body weights 10- 20 kg) and 4.0 mg/kg/day (body weights 20-50 kg) provide the same steady-state average plasma concentration as in adults receiving 200 mg/day.

Bodyweight Cl (l/hour)
10 kg 0,96
20 kg 1,61
30 kg 2,18
50 kg 3,19
70 kg 3,58

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

As an adjuvant in partial epilepsy with or without secondary generalization
  • Intravenous
    • 2 years up to 18 years and ≥ 20 kg
      • Initial dose: 1 - 2 mg/kg/day in 2 doses. Max: 100 mg/day.
      • Maintenance dose: 1 - 4 mg/kg/day in 2 doses. Max: 200 mg/day.
    • 2 years up to 18 years and 10 up to 20 kg
      • Initial dose: 1 - 2.5 mg/kg/day in 2 doses.
      • Maintenance dose: 1 - 5 mg/kg/day in 2 doses.
  • Oral
    • 2 years up to 18 years and ≥ 20 kg
      • Initial dose: 1 - 2 mg/kg/day in 2 doses. Max: 100 mg/day.
      • Maintenance dose: 1 - 4 mg/kg/day in 2 doses. Max: 200 mg/day.
    • 2 years up to 18 years and 10 up to 20 kg
      • Initial dose: 1 - 2.5 mg/kg/day in 2 doses.
      • Maintenance dose: 1 - 5 mg/kg/day in 2 doses.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Psychomotor hyperactivity. Behavioural disorders and suicidal thoughts have been reported more often in children than in adults. 

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIEPILEPTICS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Barbiturates and derivatives
N03AA02
N03AA03
Hydantoin derivatives
N03AB02
Succinimide derivatives
N03AD01
Benzodiazepine derivatives
N03AE01
Carboxamide derivatives
N03AF01
N03AF02
N03AF03
Fatty acid derivatives
N03AG01
N03AG04
Other antiepileptics
N03AX24
N03AX10
N03AX26
N03AX18
N03AX09
N03AX14
N03AX22
N03AX16
N03AX17
N03AX03
N03AX11
N03AX15

References

  1. UCB Pharma S.A., SmPC Briviact Drank ( EU/1/15/1073/021) Rev 15. 17-03-2022, www.ema.europa.eu
  2. UCB Pharma S.A., SmPC Briviact ( EU/1/15/1073/022) Rev 15. 17-03-2022
  3. UCB, SmPC Briviact 10mg/25mg/50mg/75mg/100mg Filmtabletten (EU/1/15/1073/001), 07/2018
  4. UCB, SmPC Briviact 10mg/ml Injektions-/Infusionslösung (EU/1/15/1073/022), 07/2018
  5. UCB, SmPC Briviact 10mg/ml Lösung zum Einnehmen (EU/1/15/1073/021), 07/2018
  6. Online GL. Gelbe Liste Online, https://www.gelbe-liste.de/, Accessed April 15, 2019

Changes

Therapeutic Drug Monitoring


Overdose